Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACH-0144471 in untreated paroxysmal nocturnal hemoglobinuria
2016-002652-25Phase 2Completed
- Sponsor
- Achillion Pharmaceuticals
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Achillion Pharmaceuticals. Primary endpoint: Relative decrease in lactate dehydrogenase from baseline. Started Oct 2017; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2016-002652-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002652-25.